AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Context Therapeutics to Present at Biotech Showcase 2020

January 7, 2020 GMT
Context Therapeutics to Present at Biotech Showcase 2020
Context Therapeutics to Present at Biotech Showcase 2020

PHILADELPHIA--(BUSINESS WIRE)--Jan 7, 2020--

Context Therapeutics, a clinical-stage biopharmaceutical company dedicated to advancing medicines for hormone driven cancers, today announced that chief executive officer Martin Lehr will deliver a corporate presentation at Biotech Showcase ™  2020, being held January 13-15, 2020, at the Hilton San Francisco Union Square in San Francisco.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200107005120/en/

Martin Lehr, Co-Founder & CEO (Photo: Business Wire)

During the presentation, Mr. Lehr will provide updates on Context’s lead clinical program, onapristone extended release (onapristone ER), including the Company’s ongoing Phase 2 study (ONWARD 220) evaluating onapristone ER alone in patients with progesterone receptor positive (PR+) rare ovarian and endometrial cancers, and pending combination trials in ER+,PR+,HER2- breast cancer.

Details for this presentation are as follows:

To schedule a meeting with the Context management team, please email info@contexttherapeutics.com.

About Onapristone ER

Onapristone ER (onapristone extended release) is a potent and specific antagonist of the progesterone receptor that is orally administered. Currently, there are no approved therapies that selectively target PR+ cancers. Preliminary preclinical and clinical data suggest that onapristone ER has anticancer activity by inhibiting progesterone receptor binding to chromatin, downregulating cancer stem cell mobilization and blocking immune evasion. Onapristone ER is currently the subject of an ongoing Phase 2 clinical trial in progesterone receptor positive ovarian cancer. Additional Phase 2 clinical trials in breast and endometrial cancers will initiate in 2020. Onapristone ER is an investigational drug that has not been approved for marketing by any regulatory authority.

About Context Therapeutics®

Context Therapeutics LLC is a clinical-stage biopharmaceutical company advancing medicines to treat hormone driven cancers. Context’s lead program is onapristone ER, an investigational Phase 2 drug that is being developed for progesterone receptor positive (PR+) breast, ovarian and endometrial cancers. For more information on Context, visit  www.contexttherapeutics.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200107005120/en/

CONTACT: Company Contact:

Martin Lehr

Co-Founder & Chief Executive Officer

info@contexttherapeutics.comMedia Contact:

Heather Anderson

6 Degrees

980-938-0260

handerson@6degreespr.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA PENNSYLVANIA

INDUSTRY KEYWORD: WOMEN HEALTH BIOTECHNOLOGY CLINICAL TRIALS ONCOLOGY PHARMACEUTICAL RESEARCH CONSUMER SCIENCE

SOURCE: Context Therapeutics LLC

Copyright Business Wire 2020.

PUB: 01/07/2020 02:30 PM/DISC: 01/07/2020 02:30 PM

http://www.businesswire.com/news/home/20200107005120/en